{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:52:35Z","timestamp":1789674755078,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["U10EY024526"],"award-info":[{"award-number":["U10EY024526"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["U10EY024527"],"award-info":[{"award-number":["U10EY024527"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["U10EY024531"],"award-info":[{"award-number":["U10EY024531"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ophtha.2024.11.021","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T17:16:09Z","timestamp":1732814169000},"page":"527-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0558-9793","authenticated-orcid":false,"given":"John","family":"Gonzales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-6818","authenticated-orcid":false,"given":"Nisha R.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-1091","authenticated-orcid":false,"given":"Elizabeth A.","family":"Sugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyce E.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert T.","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8216-4620","authenticated-orcid":false,"given":"Vishali","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Lightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1554-3211","authenticated-orcid":false,"given":"Michael M.","family":"Altaweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2967-4792","authenticated-orcid":false,"given":"John H.","family":"Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet T.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-1361","authenticated-orcid":false,"given":"Douglas A.","family":"Jabs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ophtha.2024.11.021_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2024.11.021_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1076\/ocii.11.1.29.15582","article-title":"Cystoid macular edema in uveitis","volume":"11","author":"Okhravi","year":"2003","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"10.1016\/j.ophtha.2024.11.021_bib3","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","article-title":"Impact of macular edema on visual acuity in uveitis","volume":"113","author":"Lardenoye","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2024.11.021_bib4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2013.09.023","article-title":"Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema","volume":"121","author":"Levin","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2024.11.021_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ophtha.2020.08.035","article-title":"Seven-year outcomes of uveitic macular edema: the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study results","volume":"128","author":"Tomkins-Netzer","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2024.11.021_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular Triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ophtha.2024.11.021_bib7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2023.04.011","article-title":"Intravitreal therapy for uveitic macular edema-ranibizumab versus methotrexate versus the dexamethasone implant: the MERIT Trial results","volume":"130","author":"Acharya","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.11.021_bib8","series-title":"Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines","author":"Brody","year":"2012"},{"issue":"8","key":"10.1016\/j.ophtha.2024.11.021_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jclinepi.2010.02.005","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Schulz","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.ophtha.2024.11.021_bib10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ajo.2011.05.028","article-title":"Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography","volume":"152","author":"Sugar","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2024.11.021_bib11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/IAE.0000000000000524","article-title":"Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds","volume":"35","author":"Reid","year":"2015","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ophtha.2024.11.021_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/archopht.122.3.336","article-title":"Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial","volume":"122","author":"Gillies","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2024.11.021_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2024.11.021_bib14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/bjo.2006.113167","article-title":"Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema","volume":"91","author":"Gillies","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2024.11.021_bib15","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1111\/j.1755-3768.2011.02247.x","article-title":"Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema","volume":"90","author":"Sallam","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2024.11.021_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ajo.2006.06.002","article-title":"Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma","volume":"142","author":"Hardwig","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2024.11.021_bib17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/IAE.0b013e3181754231","article-title":"The safety of intraocular methotrexate in silicone-filled eyes","volume":"28","author":"Hardwig","year":"2008","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ophtha.2024.11.021_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40123-021-00345-2","article-title":"Real-world safety outcomes of intravitreal ranibizumab biosimilar (Razumab) therapy for chorioretinal diseases","volume":"10","author":"Chakraborty","year":"2021","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024007462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024007462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:13:41Z","timestamp":1745219621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024007462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0161642024007462"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.11.021","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}